Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 2 8Phase 1/2 7Phase 3 2

Status

Active not recruiting 3Not yet recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 3NIH 3INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

CNS 4Tumor-Agnostic 1Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Neurofibromatosis 1 4Pancreatic Neoplasms 1Pain 1Neurofibrosarcoma 1Neurofibroma, Plexiform 1Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

pembrolizumab 210Cyclophosphamide 122Nivolumab 109Carboplatin 92fludarabine 81Gemcitabine 76Specimen Handling 74Bevacizumab 72venetoclax 70Injections 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 53Ipilimumab 50Temozolomide 45Docetaxel 42Azacitidine 42Pemetrexed 41Lenalidomide 41Oxaliplatin 40Rituximab 39Radiotherapy 39Fluorouracil 39Cetuximab 37durvalumab 36Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1/2 × AZD 6244 × 1 year × Clear all
NCT07619521 2026-06-02

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
31 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01362803 2026-06-01

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
99 enrolled 1 FDA
CNS

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT01089101 2026-05-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
217 enrolled
CNS

Astrocytoma, Neurofibromatosis 1

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT05309668 2025-12-18

SPRINKLE

AstraZeneca

Phase 1/2 Active not recruiting
36 enrolled 37 charts
CNS

Neurofibromatosis 1

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06735820 2025-07-03

MEKMDM2

Children's National Research Institute

Phase 1/2 Not yet recruiting
45 enrolled
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡